Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubamatamab alone or with cemiplimab in recurrent MUC16-positive ovarian and other gynecologic cancers
2024-510783-23-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC) and 2 more comparing Ubamatamab monotherapy with Ubamatamab + cemiplimab (2 arms). Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 5 more. Planned start Oct 2020; status: authorised.
02
Drugs
ubamatamabcemiplimab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)endometrial cancer (EC)cancer
Beyond the preview
Go deeper on 2024-510783-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510783-23-00.